ADAM Metalloproteinases as Potential Drug Targets

被引:22
|
作者
Camodeca, Caterina [1 ]
Cuffaro, Doretta [1 ]
Nuti, Elisa [1 ]
Rossello, Armando [1 ]
机构
[1] Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy
关键词
Metalloendopeptidases; ectodomain shedding; adhesion molecules; hydroxamate inhibitors; zincbinding group; small molecules; NECROSIS-FACTOR-ALPHA; CELL-ADHESION MOLECULE; GROWTH-FACTOR RECEPTOR; AMYLOID PRECURSOR PROTEIN; CONVERTING-ENZYME TACE; TNF-ALPHA; CATALYTIC-ACTIVITY; DISINTEGRIN ADAM8; ECTODOMAIN CLEAVAGE; SECRETASE CLEAVAGE;
D O I
10.2174/0929867325666180326164104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ADAMs, together with ADAMTSs and snake venom metalloproteases (SVMPs), are members of the Adamalysin family. Differences in structural organization, functions and localization are known and their domains, catalytic or non-catalytic, show key roles in the substrate recognition and protease activity. Some ADAMs, as membrane-bound enzymes, show sheddase activity. Sheddases are key to modulation of functional proteins such as the tumor necrosis factor, growth factors, cytokines and their receptors, adhesion proteins, signaling molecules and stress molecules involved in immunity. These activities take part in the regulation of several physiological and pathological processes including inflammation, tumor growth, metastatic progression and infectious diseases. On these bases, some ADAMs are currently investigated as drug targets to develop new alternative therapies in many fields of medicine. This review will be focused on these aspects.
引用
收藏
页码:2661 / 2689
页数:29
相关论文
共 50 条
  • [21] The emerging role of ADAM metalloproteinases in immunity
    Lambrecht, Bart N.
    Vanderkerken, Matthias
    Hammad, Hamida
    NATURE REVIEWS IMMUNOLOGY, 2018, 18 (12) : 745 - 758
  • [22] Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer
    Roy, Roopali
    Yang, Jiang
    Moses, Marsha A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5287 - 5297
  • [23] Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies
    Itoh, Yoshifumi
    MATRIX METALLOPROTEINASES AND TISSUE REMODELING IN HEALTH AND DISEASE: TARGET TISSUES AND THERAPY, 2017, 148 : 327 - 338
  • [24] Matrix Metalloproteinases and Endometriosis: Their Role in Disease Pathophysiology and Potential as Therapeutic Targets
    Alali, Zahraa
    Swan, Kimberly
    Nothnick, Warren B.
    CURRENT WOMENS HEALTH REVIEWS, 2018, 14 (02) : 147 - 153
  • [25] The A Disintegrin And Metalloproteases ADAM10 and ADAM17 as potential novel targets in multiple myeloma
    Burger, R.
    Klenner, B.
    Klausz, K.
    Staudinger, M.
    Garbers, C.
    Guenther, A.
    Gramatzki, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 84 - 84
  • [26] Role of matrix metalloproteinases in diabetic foot ulcers: Potential therapeutic targets
    Fu, Kang
    Zheng, Xueyao
    Chen, Yuhan
    Wu, Liuying
    Yang, Zhiming
    Chen, Xu
    Song, Wei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [27] Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
    Kucukguven, Arda
    Khalil, Raouf A.
    CURRENT DRUG TARGETS, 2013, 14 (03) : 287 - 324
  • [28] Tumour microenvironment - Opinion - Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
    Overall, CM
    Kleifeld, O
    NATURE REVIEWS CANCER, 2006, 6 (03) : 227 - 239
  • [29] Potential drug targets and treatment of schizophrenia
    Kumar, Anil
    Yadav, Monu
    Parle, Milind
    Dhingra, Sameer
    Dhull, Dinesh K.
    INFLAMMOPHARMACOLOGY, 2017, 25 (03) : 277 - 292
  • [30] Editorial: Metalloenzymes: Potential Drug Targets
    Iqbal, Jamshed
    Jacob, Claus
    Sevigny, Jean
    FRONTIERS IN PHARMACOLOGY, 2021, 12